Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal
antibodies such as trastuzumab can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and
trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.